LDS/Medical Tests/Calcitonin (Thyrocalcitonin)

Calcitonin (Thyrocalcitonin)

Human calcitonin is a 32-amino-acid polypeptide hormone secreted by the parafollicular C cells of the thyroid. The physiological role of calcitonin is still not well defined although we do know calcitonin is involved in calcium homeostasis, and its secretion is regulated mainly by extracellular calcium concentration. Interestingly, calcitonin specifically binds to osteoclasts, and it has been suggested that it has an inhibiting role on bone formation, such as the calcitonin “knock-out” gene experiment in mice that showed a significant increase in bone formation.

Calcitonin is metabolized predominantly by the kidney. It is used in the detection and confirmation of C cell hyperplasia and as a tumor marker for the diagnosis and management of medullary carcinoma of the thyroid gland. Calcitonin is not useful as a screening test because false negatives can be obtained through the baseline results. Although certain indications do justify monitoring with this test such as: family history of thyroid cancer, calcified thyroid mass, etc. It should be noted that the peptide is frequently elevated in leukemias and myeloproliferative disorders. In addition, it may be produced ectopically by tumors, e.g. those of the lung and breast. Evaluation may also be seen in connection with hyperthyroidism, hypergastrinemia, renal failure, and chronic inflammatory disease. Other substances such as pentagastrin, β-adrenergic agonists, growth hormone-releasing hormone, and other gastrointestinal peptides can also stimulate calcitonin release from parafollicular C cells yielding elevated levels.

  • In diagnosis of medullary thyroid carcinoma
  • As an aid in diagnosis of parafollicular C cell hyperplasia
  • Monitoring and management of recurrent tumor after treatment in medullary thyroid carcinoma
  • Can be used to screen relatives of patients with medullary carcinoma of thyroid

Increased in:

  • Medullary thyroid carcinoma
  • Leukemias
  • Myeloproliferative disorders
  • Carcinoma (breast, lung, pancreas, neuroendocrine)
  • Chronic renal failure

Male 3 years and older: 0.0 - 7.5 pg/mL (ng/L)
Female 3 years and older: 0.0 - 5.1 pg/mL (ng/L)
 

 

.

Chemiluminescent Immunoassay, Radioimmunoassay (RIA), Enzyme immunoassay (EIA), ELISA.

Serum (SST) or Plasma Heparin (Green).

Stability

  • Ambient: 8 hours
  • Refrigerated: 1 week
  • Frozen: 1 year
Calcium, Carcinoembryonic antigen (CEA), Ionized calcium, phosphor, calcitonin gene related peptide, histaminase, thyroglobulin, Fine Needle Aspiration, thyroid panel (T3, T4, TSH), cortisol.
Same day.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Best Pract Res Clin Endocrinol Metab. 2008; (6):941-53 [PMID: 19041824]
  • J Clin Endocrinol Metab. 2004;89:163. [PMID: 14715844]
  • Nat Clin Pract Endocrinol Metab. 2009; (1):35-44 [PMID: 19079272]
  • Curr Opin Oncol. 2007;19:18. [PMID: 17133107]
  • Alan Wu. Tietz Clinical Guide to Laboratory Tests, Fourth Edition. Saunders; 4 edition (June 13, 2006). ISBN-10: 0721679757